Observational study to investigate safety and effectiveness of lorlatinib as first line treatment for ALK-gene rearranged unresectable advanced/recurrent NSCLC patients in Japan clinical setting

05/06/2024
13/04/2026
EU PAS number:
EUPAS1000000117
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Non-Interventional Study Protocol_Ver1.0_reducted.pdf

English (430.63 KB - PDF) View document
Updated protocol

Ver6.0 Non-Interventional Study Protocol.pdf

First published: 09/04/2026
English (699.09 KB - PDF) View document

Non-Interventional Study Protocol_Ver2.0_reducted.pdf

First published: 04/06/2024
English (656.81 KB - PDF) View document
Study results
Study report
Other information